Wedbush Reaffirms “Outperform” Rating for Kiniksa Pharmaceuticals (NASDAQ:KNSA)
Wedbush restated their outperform rating on shares of Kiniksa Pharmaceuticals (NASDAQ:KNSA – Free Report) in a research note issued to investors on Tuesday morning, RTT News reports. The firm currently has a $30.00 price objective on the stock, up from their prior price objective of $28.00. Wedbush also issued estimates for Kiniksa Pharmaceuticals’ FY2027 earnings […]
More Stories
Trump Calls for Temporary 10 Percent Cap on Credit Card Interest Rates
By Aldgra Fredly President Donald Trump said on Jan. 9 that he would call for a one-year cap on credit...
Trump Declares National Emergency to Shield Venezuelan Oil Revenues Held in US Custody
By Tom Ozimek President Donald Trump signed an executive order on Jan. 9 declaring a national emergency to block courts...
Operation Salvo Leads to Arrest of 54 Individuals in New York City: DHS
By Naveen Athrappully Authorities have arrested 54 individuals in New York under Operation Salvo, an immigrant enforcement operation that was...
DHS Launches Fraud Investigation Into Minnesota Refugee Program
By Savannah Hulsey Pointer The U.S. Citizenship and Immigration Services (USCIS) has launched an investigation in Minnesota, joining other federal...
Greenland Should Talk to US Without Denmark, Opposition Leader Says
By Rachel Roberts Greenland should hold talks with the United States government without Denmark being present, a Greenlandic opposition leader...
Musk’s xAI Plans $20 Billion Mississippi Data Center in Largest Investment in State History
By Evgenia Filimianova Elon Musk’s artificial intelligence startup xAI plans to invest more than $20 billion to build a large...